Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510);A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma

Cancer

Volumn 118, Issue 12, 2012, Pages 3128-3134

  Cheson, Bruce D ^a   Bartlett, Nancy L ^b   Vose, Julie M ^c   Lopez Hernandez, Andres ^d   Seiz, Amanda L ^e   Keating, Anne T ^e   Shamsili, Setareh ^e  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Biological therapy; Clinical trial; Diffuse large B cell; Non Hodgkin's lymphoma; Survivin

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; SEPANTRONIUM BROMIDE; VINCRISTINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CAVA VEIN DISEASE; CAVA VEIN THROMBOSIS; CLINICAL ARTICLE; CONFUSION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 84861844082     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27384     Document Type: Erratum

References (14)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-95. (Pubitemid 28363044)
2. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-26. (Pubitemid 46211317)
3. Verdecia MA, Huang H-K, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol. 2000;7:602-608. (Pubitemid 30445919)
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921. (Pubitemid 27353455)
5. Tracey L, Pêrez-Rosado A, Artiga MJ, et al. Expression of the NK-kB targeta BCL-2 and BIRCS/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005;206:123-134. (Pubitemid 40754015)
6. Giodini A, Kallio MJ, Wall NR, et al. Regulation of micro-tubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462-2467. (Pubitemid 34462718)
7. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67:8014-8021. (Pubitemid 47395135)
8. Satoh M, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3872-3880.
9. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharma-cokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;32:5198-5203.
10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
11. Lewis KD, Samlowski W, Ward J, et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011;29:161-166.
12. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155 a small-molecule suppressor of survivn, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27:4481-4486.
13. Kita A, Nakahara T, Yamanaka K, et al. Antitumor effects of YM155, a novel survivin suppressant, against aggressive non-Hodgkin lymphoma. Leuk Res. 2011 Jan 13 [Epub ahead of print].
14. Mitsuoka K, Miyoshi S, Kita A, et al. Effect of YM155, a potent survivin suppressantm on the antitumor effect of rituximab in diffuse large B-cell lymphomas (DLBCL) xeno-graft models: FLT-/FDG-PET imaging studies. J Clin Oncol. 2010;28(15s):abstract #8087).